{
    "clinical_study": {
        "@rank": "31680", 
        "brief_summary": {
            "textblock": "This is a single arm, open-label study which will be opened at specific clinical sites at\n      the request of an investigator for the treatment of individual subjects for whom there are\n      no other treatment options. Subjects will be treated for 24 weeks with sofosbuvir (400mg QD)\n      with RBV; pegylated interferon may be added at the discretion of the investigator."
        }, 
        "brief_title": "Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C", 
        "condition": "Post-transplant Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > or = 18 years\n\n          -  Previously undergone orthotopic liver transplant (OLT) at least 2 months prior to the\n             planned start of dosing\n\n          -  Aggressive Hepatitis C infection (including fibrosing cholestatic hepatitis C)\n\n          -  Life expectancy of < 12 months if the HCV is left untreated\n\n        Exclusion Criteria:\n\n          -  History of clinically significant drug allergy to nucleoside/nucleotide analogs\n\n          -  Participation in a clinical study with an investigational drug or biologic within 1\n             month prior to anticipated dose administration, unless information is available to\n             determine that there is no safety or drug-drug interaction risk to the subject\n\n          -  Unable or unwilling to follow the contraception requirements"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "id_info": {
            "nct_id": "NCT01779518", 
            "org_study_id": "GS-US-334-0139"
        }, 
        "intervention": [
            {
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GS-7977", 
                    "PSI-7977", 
                    "Sovaldi\u2122"
                ]
            }, 
            {
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Pegylated Interferon", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Infective Agents", 
                "Interferons", 
                "Ribavirin", 
                "Molecular Mechanisms of Pharmacological Action"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "HCV", 
            "Sustained Virologic Response", 
            "Direct Acting Antiviral", 
            "GS-7977", 
            "Pegylated interferon", 
            "Ribavirin", 
            "Open Label", 
            "Sofosbuvir", 
            "Liver transplant", 
            "Hepatitis", 
            "Hepatitis, Chronic", 
            "Hepatitis C", 
            "Hepatitis C, Chronic", 
            "Liver Diseases", 
            "Digestive System Diseases", 
            "Hepatitis, Viral, Human", 
            "Virus Diseases", 
            "Enterovirus Infections", 
            "Picornaviridae Infections", 
            "RNA Virus Infections", 
            "Flaviviridae Infections", 
            "Antiviral Agents", 
            "Anti-Infective Agents", 
            "Therapeutic Uses", 
            "Pharmacologic Actions", 
            "Antimetabolites", 
            "Molecular Mechanisms of Pharmacological Action"
        ], 
        "lastchanged_date": "January 15, 2014", 
        "official_title": "An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection", 
        "overall_status": "Approved for marketing", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779518"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "January 2014"
    }
}